BioXcel Stock Plummets Amid Fraud Investigation and Data Issues in Alzheimer's Trial
BioXcel Therapeutics (BTAI) experienced a significant drop in stock value after revealing a fraud investigation at its largest study site. The investigation was prompted by a fraudulent email chain from a clinical site that enrolled 40% of the patients in the study. Despite the investigation, BioXcel remains confident in the positive results of its dissolvable tablet, which significantly reduced agitation symptoms in Alzheimer's patients. The company plans to request approval for the tablet in the Alzheimer's population, as it could be a game-changer for managing agitation episodes and allowing patients to stay at home longer.